{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 56,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/17",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.18,
        "y": 0.38
      },
      "kind": "callout",
      "text": "NXC-201 – 100% ORR. One-time treatment | Monotherapy | All Relapsed/Refractory ALA Patients. 32,752 Eligible U.S. AL Amyloidosis Patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b6c543a-d68d-4ca1-a0e6-88dda4d9ef19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.15,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "image",
      "text": "Johnson & Johnson, Prothena, AstraZeneca, Caelum Biosciences",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54af845c-8af3-474d-96b4-725d3415ba6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Relapsed/Refractory ~3,040",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11c7bf37-fffb-434c-a682-0cfc319f5ea1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Estimated relapsed/refractory US Prevalence ~29,712 in 2023 (Previously Treated)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "502f0dd5-f174-497e-a0b7-724f905b79e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Newly diagnosed US Incidence ~4,000",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76cca19c-c42a-4808-9071-80e99a3a6d02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.55,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Eligible R/R ALA Patients ~32,752",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9087a0e5-8bbd-493c-852a-6669560efaa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.4,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Blue Ocean Opportunity: No FDA Approved Drugs in Relapsed / Refractory AL Amyloidosis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c15f5913-97b6-47ce-8bda-b5d5529c9644",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Note: Public information development plans as of 2023. Dara-CyBorD: Daratumumab, Bortezomib + cyclophosphamide + dexamethasone...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29307e9d-e1be-4a0e-8a7d-ba460a1f49dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a60d17a8-4887-47eb-88b6-db3343175cd2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "eaada0be-8c37-4154-baae-040c41f1c2b9",
      "evidence": "32,752 Eligible U.S. AL Amyloidosis Patients",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 17,
      "beatId": "554702d9-4f5c-4012-bea2-07d35084ca95",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slide 17: NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9e3ff9b5-ae74-4c1c-8a8b-4b20ea131916",
      "evidence": "Slides 16-23 present clinical trial results and market opportunity for NXC-201",
      "position": 1,
      "objective": "What are the potential benefits of NXC-201 in the market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}